Gross, Kenneth M.Bremner, William J.2008-10-172008-10-171987-08Am J Med. 1987 Aug;83(2):359-61http://hdl.handle.net/1773/4445A 60-year-old man with stage D2 prostatic carcinoma received treatment with a new luteinizing hormone-releasing hormone superagonist. After a seven-month remission; relapse of the disease occurred and an adrenal-suppressing dose of dexamethasone was added. The resulting combined gonadal and adrenal suppression led to another remission that lasted five months. This case supports other observations of the importance of adrenal androgen production in the pathobiology of prostatic carcinoma.en-US5-alpha reductase inhibitorsgonadotropinstestosteronereifenstein's syndromeklinefelter's syndromespermatogenesisandrologymale contraceptioncolchicineLymphatic MetastasisHumansMiddle AgedNeoplasm Recurrence, Local, drug therapy, pathologyMaleAntineoplastic Combined Chemotherapy Protocols, therapeutic useResearch Support, U.S. Gov't, Non-P.H.S.Prostate, pathologyProstatic Neoplasms, drug therapy, pathologyTime FactorsNafarelinDexamethasone, administration & dosageGonadorelin, administration & dosage, analogs & derivativesBiopsyRemission InductionAdenocarcinoma, drug therapy, pathologyResearch Support, U.S. Gov't, P.H.S.Article